James Topper

James Topper joined Frazier Healthcare in 2003 as a Venture Partner and became a General Partner in 2005.James Topper is a member of the firm's Biopharma Venture team. Since joining Frazier Healthcare, James Topper has led multiple Biopharma Venture investments including Incline Therapeutics that was acquired by The Medicines Company for up to $390 million, Calistoga Pharmaceuticals that was acquired by Gilead in April 2011 for total consideration of up to $600 million, Alnara Pharmaceuticals that was acquired by Eli Lilly for total consideration of up to $390 million, and Cotherix (Nasdaq CTRX) that was acquired by Actelion for $420 million and a successful PIPE investment in Threshold Pharmaceuticals (Nasdaq THLD). James Topper currently serves on the boards of Amicus Therapeutics (Nasdaq FOLD), Atterocor, Semnur Pharmaceuticals, Portola Pharmaceuticals, Anaptys Biosciences, Allena Pharmaceuticals, Alcresta and Rempex Pharmaceuticals. In 2011 James Topper was named to the Forbes Midas list representing the top 100 venture capitalists.